KR101640890B1 - Composition of infant liquid formula including goat milk - Google Patents
Composition of infant liquid formula including goat milk Download PDFInfo
- Publication number
- KR101640890B1 KR101640890B1 KR1020150116254A KR20150116254A KR101640890B1 KR 101640890 B1 KR101640890 B1 KR 101640890B1 KR 1020150116254 A KR1020150116254 A KR 1020150116254A KR 20150116254 A KR20150116254 A KR 20150116254A KR 101640890 B1 KR101640890 B1 KR 101640890B1
- Authority
- KR
- South Korea
- Prior art keywords
- milk
- composition
- casein
- weight
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 239000007788 liquid Substances 0.000 title claims abstract description 51
- 235000020251 goat milk Nutrition 0.000 title abstract description 29
- 239000005018 casein Substances 0.000 claims abstract description 34
- 235000018102 proteins Nutrition 0.000 claims abstract description 30
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000021240 caseins Nutrition 0.000 claims abstract description 23
- 210000004080 milk Anatomy 0.000 claims description 66
- 235000013336 milk Nutrition 0.000 claims description 65
- 239000008267 milk Substances 0.000 claims description 65
- 239000002245 particle Substances 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 12
- 239000011782 vitamin Substances 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 12
- 229930003231 vitamin Natural products 0.000 claims description 12
- 239000003925 fat Substances 0.000 claims description 11
- 235000021248 S1-casein Nutrition 0.000 claims description 10
- 238000000265 homogenisation Methods 0.000 claims description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 9
- 239000011707 mineral Substances 0.000 claims description 9
- 239000003995 emulsifying agent Substances 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 239000004033 plastic Substances 0.000 claims description 6
- 229920003023 plastic Polymers 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 210000002445 nipple Anatomy 0.000 claims description 4
- 102000011632 Caseins Human genes 0.000 abstract description 40
- 108010076119 Caseins Proteins 0.000 abstract description 40
- 238000010521 absorption reaction Methods 0.000 abstract description 26
- 230000029087 digestion Effects 0.000 abstract description 22
- 235000013350 formula milk Nutrition 0.000 abstract description 12
- 102000009366 Alpha-s1 casein Human genes 0.000 abstract description 10
- 108050000244 Alpha-s1 casein Proteins 0.000 abstract description 10
- 235000021247 β-casein Nutrition 0.000 abstract description 10
- 230000001079 digestive effect Effects 0.000 abstract description 7
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 4
- 230000007815 allergy Effects 0.000 abstract description 4
- 208000026935 allergic disease Diseases 0.000 abstract description 3
- 238000005457 optimization Methods 0.000 abstract description 3
- 235000008476 powdered milk Nutrition 0.000 abstract description 3
- 210000000481 breast Anatomy 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 30
- -1 sphingomyelin Substances 0.000 description 19
- 235000014113 dietary fatty acids Nutrition 0.000 description 16
- 239000000194 fatty acid Substances 0.000 description 16
- 229930195729 fatty acid Natural products 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 241000283707 Capra Species 0.000 description 11
- 210000004051 gastric juice Anatomy 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 235000016709 nutrition Nutrition 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 235000020183 skimmed milk Nutrition 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 102000007544 Whey Proteins Human genes 0.000 description 7
- 108010046377 Whey Proteins Proteins 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 235000020256 human milk Nutrition 0.000 description 7
- 210000004251 human milk Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 235000021119 whey protein Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 235000021246 κ-casein Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108050001786 Alpha-s2 casein Proteins 0.000 description 3
- 102000008192 Lactoglobulins Human genes 0.000 description 3
- 108010060630 Lactoglobulins Proteins 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011469 Crying Diseases 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019621 digestibility Nutrition 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000020191 long-life milk Nutrition 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241001057184 Axion Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XYAUIVRRMJYYHR-UHFFFAOYSA-N acetic acid;propane-1,2,3-triol Chemical class CC(O)=O.OCC(O)CO XYAUIVRRMJYYHR-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003508 chemical denaturation Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 239000011706 ferric diphosphate Substances 0.000 description 1
- 235000007144 ferric diphosphate Nutrition 0.000 description 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 1
- 229940036404 ferric pyrophosphate Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000020189 fortified milk Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/15—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
- A23C9/1512—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins containing isolated milk or whey proteins, caseinates or cheese; Enrichment of milk products with milk proteins in isolated or concentrated form, e.g. ultrafiltration retentate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A23L1/296—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/26—Homogenisation
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
The present invention relates to a liquid preparation composition containing a goat milk. More specifically, the present invention relates to a liquid preparation composition which is improved in digestion and absorption of infants and young children due to the milk-friendly combination of goat milk.
The process of human growth and development is divided into the fetal period, infancy, infancy, childhood, adolescence, adulthood, and youthfulness. In particular, nutritional intake should be taken into account in the case of infants, since it is a period in which body growth rate is high and comprehensive nutrients are highly needed. Breastfeeding is considered the most desirable and natural way of nutrition in that infants have the right amount and essential nutrients in their growth or development. However, actual breastfeeding is not easy due to the recent increase in the number of working women.
Preparative oil is one of the artificial nutrition methods for babies, which is supplemented with defects in the constituents of milk and blended with various ingredients to form a milk-like composition. Currently, most of the manufactured products are commercialized starting from milk-derived ingredients called milk milk, but the present formula has slightly different characteristics from ideal breast milk composition. In addition to these breast milk compositions, powdered milk powder that accounts for most of the current market for formula milk should be supplied to infants and to be correctly fed with the nutritional ingredients designed when they are dissolved in liquid form for lactation. The concentration, solubility, Acid, and temperature conditions are not accurately fed. In addition, the liquid formulated milk for feeding with a uniform milking concentration has not been able to be largely deviated from the general milking level in terms of nutritional components, and thus it has been difficult to achieve the preparation of milk preparation and proper nutritional supply.
Conventional preparation milk tried to have similarity with the composition of milk, protein, fat and carbohydrates as a part of breastfeeding, but this is basically possible also in milk-derived ingredients. The casein that is conventionally classified can be roughly divided into casein and whey protein. The casein is usually divided into αS1-casein, αS2-casein, β-casein, and κ-casein. Whey protein has various proteins, - lactoglobulin and a-lactalbumin are the major constituent proteins. Among these, β-casein is the main protein of breast milk, and it is easy to digest because it does not clot well under the action of gastric acid and makes soft appearance. In addition, α-S1 casein is a major ingredient in curd formation, and is a component that has a low digestibility with excessive content. However, intrinsic studies on the overall mammographic prescription for solving the problems of allergen induction and digestive substances considering the effects of α-S1 casein, β-casein and the like are still insufficient.
Typically, the preparation oil may be prepared in solid or liquid form, such as powder. Particularly, when preparing a liquid formula, it contains proteins, fats, carbohydrates, vitamins, and minerals in the preparation oil. Therefore, it is necessary to carry out preheating step for homogenization and many heat treatments such as sterilization and sterilization for maintaining microbial safety. During this process, physical and chemical denaturation of proteins will inevitably occur.
The whey protein, which is known to be a major factor in the mechanism of protein thermal degradation, involves denaturation and aggregation of the protein itself. This includes irreversible protein-protein interactions of covalent bonds and protein-protein interactions of non-covalent bonds. In the case of covalent bonds, disulfide bonds of β-lactoglobulin are typical. This can be mainly caused by sulfhydryl oxidation or sulfhydryl-disulfide exchange, and the disulfide bond (S-S) contained in cysteine and the like binds to? -Lactoglobulin to form strong aggregation leading to precipitation.
Generally, proper setting of the heat treatment conditions such as sterilization and sterilization in liquid formulated oil reduces the denaturation of proteins and other milk materials due to heat at high temperature, thereby maintaining phase stability and microbial safety, and changes in odor, discoloration and taste It is a very important factor in minimizing In the case of existing commercially available liquid formulated liquid preparations, most of them are produced through an excessive heat treatment method called retort, which causes phase instability or causes problems such as taste, odor and discoloration. In addition, in order to avoid such a phenomenon, it has been found that the content of the protein raw material, which is an essential element, is lowered and commercialized, thereby failing to supply adequate nutrition to consumers.
A problem to be solved by the present invention is to provide a liquid pharmaceutical composition having a composition close to that of milk and having an excellent digestion and absorption enhancement effect and an allergy reduction effect in infants and young children.
Another object of the present invention is to provide a process for preparing a liquid pharmaceutical composition having remarkably improved stability over time and digestion and absorption through process optimization.
The present invention provides a liquid preparation milk composition comprising at least one selected from the group consisting of milk derived from goat milk, milk powder, and proteins, and having a solid content of 5 to 40 wt% based on the total weight of the composition.
DISCLOSURE OF THE INVENTION As a result of intensive researches to overcome the problems of the prior arts, the present inventors have found that when a liquid preparation composition contains a raw material derived from a goat milk (chlorine milk), the content of αS1- casein, which is a main protein forming a curd, The present invention has been completed with the surprising discovery that the content of? -Casein which keeps curd smooth is high, which is remarkably effective in reducing allergies of a baby sensitive to milk protein, which is easy to digest and absorb when infants are ingested.
Goat milk has lower total casein content than milk and has relatively similar milk and protein composition. The curd characteristic of goat milk is known to be small and smooth compared to milk. It is known that the amount of curd precipitated at the top is also very low at 2% level of goat milk compared to 10% of milk. Compared to the hydrolysis rate, milk casein is completely hydrolyzed, whereas milk is known to be degraded to about 75 to 90%. In case of goat milk, about 95% is relatively similar to breast milk. These goat milk contains a large amount of vitamins and minerals, which have good bioavailability and absorption rate. It is also known that the absorption of nutrients such as calcium, phosphorus, and manganese is superior to milk. Lactoglobulin is relatively low in goat milk as compared to milk-based materials, and thus the goat milk is more advantageous than the milk-derived material in stabilizing the liquid preparation composition.
Goat milk also shows different characteristics in terms of fat content and composition compared to milk. It is commonly known that the lipid content of goat milk is higher than that of milk, and the lipid digestibility is higher than that of milk. In the case of the middle chain fatty acid, which is mostly contained in the goat milk, since the melting point is low and the hydrolysis rate is high due to the nature of the fatty acid, digestion characteristics are improved, so that bile acid for digestion is less needed. Ultimately, this effect makes the goat milk easier to digest and absorb, and thus it can be used more advantageously for infants with inadequate gastrointestinal function than milk intake. In addition, the goat milk has abundant components such as nucleotide, sphingomyelin, and selenium, and the improvement efficacy against atopy or allergy has been continuously reported.
Particularly, milk, milk powder and protein derived from the goat used in the present invention have a low content of? -S1 casein, which is present in milk, so that the protein does not coagulate due to stomach acid and does not interfere with digestion. In addition, these goat-derived ingredients have a high content of β-casein, similar to breast milk, and are easy to digest because the curd itself is soft.
Variations occur depending on environment and individual, but the casein composition of known breast milk is about 75% for β-casein and about 25% for κ-casein, and αS1-casein is not included. The casein composition of milk in general is about 36%, about 13% for κ-casein, about 33% for αS1-casein, about 18% for αS2-casein, The casein composition of about 62.8% of β-casein, about 10.4% of κ-casein, about 5.6% of αS1-casein and about 21.2% of αS2-casein are compared with those of αS1-casein and β- [Kim, HH, Park, YS, Yoon, SH, Food Composition of Goat Milk and Their Nutritional Value, Journal of the Korean Society of Food Science and Nutrition, Vol.46, No. 2, pp. 121 ~ 126 (2014)]
In addition, the mean diameter of the casein micelles of the goat milk is finer to the order of 80 nm, while the mean diameter of the casein micelles of the milk is 100 to 250 nm.
In the present invention, the solid content of the liquid preparation composition may be 5 to 40% by weight, preferably 6 to 30% by weight, and more preferably 7 to 25% by weight based on the total weight of the composition. When the solid content is less than 5% by weight, deficiency of nutritional ingredients is caused. When the solid content is more than 40% by weight, phase stability is deteriorated and excessive nutrients are caused.
In the present invention, the? -1-casein in the liquid pharmaceutical composition may be contained in an amount of 0.1 to 27% by weight, preferably 0.5 to 20% by weight, more preferably 1 to 15% by weight based on the total weight of the casein. When the content of the? S1-casein exceeds 27% by weight of the total casein, there arises a problem that adverse effects are exerted on the digestion and absorption of curd, etc., and it is practically difficult to make the content of the? S1-casein in the liquid preparation composition less than 0.1% by weight.
In the present invention, the? -Cases in the liquid pharmaceutical composition may be contained in an amount of 40 to 80% by weight, preferably 45 to 65% by weight based on the total weight of casein. If the content of the?-Casein is less than 40% by weight of the total casein, the effect of softening the curd hardly appears, and it is practically difficult to apply the composition in an amount exceeding 80% by weight.
The liquid preparation milk composition of the present invention may contain any one or more selected from the group consisting of milk derived from goat milk, milk powder, and proteins. The milk derived from the goat may include any one or more selected from the group consisting of sterilized milk (oil), sterilized milk, low fat milk, skim milk, fortified milk, etc. The goat milk powder may be skim milk powder, , Sweetened powdered milk, and mixed milk powder, and the protein derived from the goat may contain at least one selected from the group consisting of goat protein, agrohortic acid protein, isolate protein, whey protein, demineralized whey protein, Protein, goat milk protein, goat milk protein, and the like.
The liquid preparation milk composition of the present invention may contain milk-derived ingredients, but it is preferable that the content of? S1-casein in the composition is 0.1 to 27% by weight, preferably 1 to 20% by weight, Containing ingredient may be contained in an amount of 1 to 15% by weight, or may be free of any ingredient.
The liquid pharmaceutical composition of the present invention can be prepared by homogenization for the purpose of enhancing digestion and absorption capacity through particle refinement and stabilizing the formulation. In general, micronization and homogenization of the particles due to the optimized homogeneous effect minimizes agglomeration between the composition particles that occur over time. This results in an effect of delaying the agglomeration of the particles for a considerable time compared to the relatively large and uneven particles, and the homogenized composition has remarkably improved coagulation, separation, and precipitation of the form. Furthermore, the fineness and homogeneity of the particles not only greatly influences the stabilization of the liquid preparation milk, but also is highly effective in nutritionally improving digestion and absorption ability.
The homogenization of the liquid formulation oil composition composition has a great influence on the phase stability according to the treatment method. In the present invention, a suitable homogenization pressure is suggested for the homogeneous effect. In the present invention, the homogeneous pressure may be set to 100 to 600 bar, preferably 150 to 400 bar. When the homogeneous pressure is less than 100 bar, the homogeneous effect is insignificant and the size of the particles becomes large, which results in a nonuniform distribution and lacks phase stability. On the other hand, when the homogeneous pressure exceeds 600 bar, the particles become extremely fine, resulting in agglomeration among the particles, and the stability over time is deteriorated rather rapidly.
In the present invention, the liquid preparation milk composition may have 90% or more, preferably 95% or more of particles having a particle size of less than 0.5 占 퐉. The liquid pharmaceutical composition of the present invention can be used for the purpose of enhancing digestion, absorption and phase stability, as well as nourishing the nutritional components as described above. In the finely granulated product having a particle size distribution of less than 0.5 [ ≪ / RTI >
The liquid pharmaceutical composition of the present invention may further comprise at least one selected from the group consisting of emulsifiers, vitamins, preservatives, minerals, and the like.
An emulsifier may be further added to the liquid preparation composition of the present invention in order to stabilize emulsification dispersion during production. As the emulsifier, glycerin fatty acid esters can be used, and the glycerin fatty acid esters are compounds in which fatty acids and glycerin or polyglycerin are esterified or derivatives thereof. More specifically, the glycerin fatty acid esters include glycerin fatty acid esters, glycerin acetic acid fatty acid esters, glycerin lactic acid fatty acid esters, glycerin citric acid fatty acid esters, glycerin succinic acid fatty acid esters, glycerin diacetyl tartaric acid fatty acid esters, glycerin acetic acid esters, polyglycerin fatty acid esters, Polyglycerol condensed ricinoleic acid ester, and the like. Preferably, the emulsifier may be a glycerin fatty acid ester, a polyglycerin fatty acid ester, or a mixture thereof.
The liquid pharmaceutical composition of the present invention may further comprise vitamins for enhancing nutritional components. The vitamin is a fat soluble vitamin including vitamins A, E, D and K; And water-soluble vitamins including vitamins B1, B2, B6, B12, C, pantothenic acid, niacin, folic acid, and biotin.
The liquid formulated milk composition of the present invention may further comprise a preservative to supply saturated, unsaturated, and essential fatty acids to infants. The fat may include at least one selected from the group consisting of soybean oil, canola oil, palm olein oil, palm oil, palm kernel oil, sunflower oil, brown rice oil, corn oil and refined processed oil.
The minerals in the liquid formula oil composition of the present invention are mainly used as a nutrient source, but may additionally be included for the stabilization of the preparation oil. The mineral may include any one or more selected from the group consisting of calcium carbonate, potassium phosphate monobasic, potassium phosphate dibasic, potassium chloride, magnesium phosphate, sodium hydrogen carbonate, zinc oxide, ferric pyrophosphate, manganese sulfate, and potassium iodide have. The composition of the present invention can further reduce denaturation and solidification due to the heat treatment of the protein by additionally containing minerals. Particularly, potassium phosphate monobasic and potassium phosphate are preferable for pH buffering of the preparation liquid.
In the present invention, the liquid pharmaceutical composition may be subjected to an ultrahigh-temperature (UHT) treatment to kill microorganisms. The ultra-high temperature short-time heat treatment is a treatment technique for preserving a liquid product by? F and strong heating at a very high temperature range within a short time.
The liquid pharmaceutical composition of the present invention contains a large amount of carbohydrates, fats and proteins, and is a highly nutritious composition which is easy to propagate microorganisms when stored at room temperature and for a long time. Although there is a difference depending on the raw materials to be added, there is a large amount of microorganisms as in the case of general dairy products, and there are also cold tolerant microorganisms surviving at refrigeration temperature and thermostable microorganisms that do not kill even at high temperature heat treatment. Therefore, it is preferable that the liquid preparation composition of the present invention is subjected to an ultrahigh-temperature short-time heat treatment in order to completely kill microorganisms. This is due to less protein denaturation compared to the conventional retort method and better taste, odor, discoloration and the like compared to the retort system.
The ultrahigh-temperature short-time heat treatment may be performed at a temperature of 120 to 150 ° C, preferably 125 to 140 ° C for 1 to 60 seconds, preferably 5 to 50 seconds. If the ultra-high temperature short-time sterilization treatment is performed at a temperature of less than 120 ° C or less than 1 second, the microbial killing effect is insignificant. If the temperature is more than 150 ° C or more than 60 seconds, the thermal degeneration results in precipitation or poor thermal stability.
(S1) adding and dissolving at least one member selected from the group consisting of milk, milk powder, and proteins to the dissolved fat; (s2) homogenizing the mixture of the step (s1) so that the particles having a particle size of less than 0.5 m are not less than 90%; (s3) Sterilizing the product of the step (s2) by an ultra-short-time short-time heat treatment.
The step (s1) of the above production method may be further performed by adding a fat-soluble vitamin, an emulsifier, or a mixture thereof to the dissolved fat. In addition, the preparation method can be produced by adding water to the product after step (s1), cooling, and then adding water-soluble vitamins, minerals or a mixture thereof. In addition, the manufacturing method may further include a step of preheating the mixture before the step (s2) to improve the homogenizing effect. The homogenization of step (s2) of the above production method can be carried out at a homogenization pressure of 100 to 600 bar. Also, the ultra-high temperature short-time heat treatment in step (s3) of the above production method may be performed at a temperature of 120 to 150 DEG C for 1 to 60 seconds.
The present invention provides a liquid pharmaceutical product product in which a plastic container having a fastening portion capable of directly fastening a milk-feeding nipple is filled with the liquid preparation milk composition. Preferably, the fastening portion can be a spiral fastening portion, and a configuration can be used in which the nipple or the plastic container can be rotated to easily fasten them to each other. The above-mentioned liquid pharmaceutical product product can be conveniently milked without using a separate bottle-feeding bottle by using a plastic container which is directly fastened to the nipple, and it is possible to prevent the microbial contamination that may occur during lactation by diluting the conventional milk powder There are advantages.
The container may be made of plastic containers or glass bottles of various materials such as high density polyethylene (HDPE), low density polyethylene (LDPE), polyethylene terephthalate (PET), polypropylene (PP), polyethylene (PE) However, it is preferable to use a plastic container to fill the glass bottle because there is a risk of breaking the glass bottle.
The liquid preparation composition according to the present invention is excellent in digestion absorption and alleviating effects of infants and young children through a milk-friendly combination containing a goat's milk. The liquid preparation formula is remarkably excellent in stability over time and digestion and absorption ability through process optimization.
Fig. 1 is a photograph showing results of experiments on addition of artificial gastric juice to Comparative Example 1 and Example 5 in Experimental Example 1. Fig.
Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other various forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the present invention are provided to more fully describe the present invention to those skilled in the art and are provided for purposes of this patent.
Example Produce
Liquid formulated milk compositions were prepared according to the compositions and processes shown in Table 1 below. For the relative comparison between the goat milk and the milk used in the present example, the milk-derived skim milk powder and the skim milk-derived skim milk powder were mixed or used in accordance with the prescription to be designed so that the ratio of aS1-casein and beta-casein And other nutritional and stabilizing ingredients remained the same. In this example, the content of skim milk derived from the goat in the liquid preparation milk was gradually increased to lower the? S1-casein and to increase the? -Casein composition, and this was compared with the existing milk-derived skim milk usage prescription.
In the present invention, the method for preparing the composition of the present invention includes the steps of adding a fat-soluble vitamin, an emulsifier, lecithin, and the like to a completely dissolved fat at a high temperature and then dissolving the mixture completely at high temperature, Agitation was started with a homomixer while gradually adding. After stirring for a certain period of time, the mixture was kept at a temperature of about 40 ° C and stirred, and the ingredients derived from the goat or milk were mixed or singly added in accordance with the prescription to be designed. After a certain period of time, Milk powder, lactose and other pH adjusters, dextrin, etc. were added and stirred. After the addition of water, the mixture was cooled, and water-soluble vitamins and minerals were mixed, and the stirring was completed and finalized by preheating, homogenization, and ultrahigh-temperature short-time heat treatment (UHT).
In Experimental Example 1, the artificial gastric juice addition experiment was carried out in each example. Based on the experimental results, the digestive clinical evaluation of Experimental Example 2 was carried out.
EXPERIMENTAL EXAMPLE 1 Experiments on addition of artificial gastric juice according to the composition ratio of? S1-casein and?-Casein
(Derived from milk)
(Derived from goat)
(Derived from goat)
The addition of artificial gastric juice to the compositions of Comparative Example 1 and Examples 1 to 5, in which the ratio of casein was different according to Table 1, was carried out. FIG. 1 shows experimental results for Comparative Examples 1 and 5. As a result of the experiment on Example 5, it was confirmed that the solidification due to the artificial gastric juice was hardly appeared, unlike the Comparative Example 1. Overall, the compositions of Examples 1 to 5 showed lower coagulation due to artificial gastric juice as the ratio of αS1-casein (%) and β-casein (%) were higher than that of Comparative Example 1.
It was confirmed that the embodiments of the present invention show better digestion and absorption characteristics than the conventional milk-derived Comparative Example 1 by appropriately designing the ratio of? S1 and? -Casein to those of conventional milk-derived preparations.
Experimental Example 2: Digestive absorption clinical evaluation according to composition ratio of? S1-casein and?-Casein
The liquid preparation formula compositions of Comparative Examples 1, 2, and 5 were subjected to clinical evaluation of digestion and absorption.
beta-casein ratio (%)
result
As a result of the clinical evaluation, the digestion absorption clinical evaluation results of Examples 2 and 5 showed good characteristics compared to Comparative Example 1, and in particular, Example 5 showed better results than Example 2. In other words, the digestive absorption index (carious state, constipation, crying due to indigestion) was most excellent in Example 5.
As a result of the artificial gastric juice addition test and the digestion absorption clinical evaluation of Comparative Example 1 and Examples, the liquid preparation milk composition (Examples 1 to 5) of the present invention showed significantly higher activity of the casein protein derived from the goat , The ratio of? S1-casein and?-Casein was relatively similar to that of breast milk. As a result, it was confirmed that digestive absorption characteristics were superior to those of milk-derived comparative example 1 as a result.
The experimental methods used in Experimental Examples 1 and 2 are specifically shown below.
< Casein Analysis>
To extract protein from milk (or product), the sample stored at -20 ° C was thawed and centrifuged at 1000 g for 10 minutes to remove the fat from the upper layer. To the pretreated solution, 8 M urea, 165 mM Tris, 44 mM sodium citrate, and 0.3% (v / v) mercaptoethanol aqueous solution were added, followed by filtration through a filter paper having a pore size of 0.45 μm. This solution contained both lipid soluble casein protein and whey protein, and the filtered protein was analyzed by fast gradient HPLC on an AxION ® TOF mass spectrometer. 0.1% (v / v) trifluoroacetic acid aqueous solution and 0.1% (v / v) acetonitrile aqueous solution were used as mobile phases. The measurement results were analyzed using a Micromass Q-TOF mass spectrometer to detect proteins with a measurement range of 1000-2000 m / z. The α, β, and κ-casein protein peaks shown in the samples were quantified by contrast with the standard peaks extracted from milk, respectively.
≪ Production method of artificial gastric juice &
And 2 g of sodium chloride was added to 7 mL of hydrochloric acid and water to make a volume of 1 L, followed by stirring. Effects of Artificial Gastrointestinal and Digestive Enzyme Treatments on the Isoflavone Content of the Unglycosylated Soybeans and Soybean Bean, Korean Journal of Nutrition, Vol.36 (1), pp. 32 ~ 39 (2003)]
≪ Experiment of artificial gastric juice addition &
The same amount of artificial gastric juice prepared by the Health Functional Food Revolution method was added to each prepared liquid preparation milk and stirred. The mixture was allowed to stand for a certain period of time and observed with a microscope magnified 200 times. (◎) compared to the conventional control (Comparative Example 1). Good level (∘), equal level (△) and poor level (X) were evaluated.
<Digestion Absorption Clinical Evaluation Method>
Clinical evaluations were conducted on infants aged 3 to 15 months, selected by voluntary participation. 30 children were divided into 2 experimental groups (Example 2), 2 experimental groups (Example 5) and 2 control groups (Comparative Example 1) for a total of 6 weeks. Feeding methods were such that each infant feeds according to the usual method of ingestion, and the symptoms that may appear in infants according to the degree of digestion and absorption were used as indicators of digestion and absorption. At this time, digestive absorption index was crying according to change of state, constipation, and indigestion. The evaluation according to the result was evaluated as to whether or not the digestion and absorption index was improved in comparison with the control product (Comparative Example 1). Very good (◎) compared to the control product at the time of evaluation. Good level (∘), equal level (△) and poor level (X) were evaluated.
Claims (9)
wherein the composition comprises 0.1 to 27% by weight, based on the total weight of the casein, of? S1-casein and 40 to 80% by weight of?-casein based on the total weight of the casein.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150116254A KR101640890B1 (en) | 2015-08-18 | 2015-08-18 | Composition of infant liquid formula including goat milk |
| CN201680042883.XA CN107846914A (en) | 2015-08-18 | 2016-08-12 | Liquid containing Goat Milk modulates newborn composition |
| PCT/KR2016/008932 WO2017030330A1 (en) | 2015-08-18 | 2016-08-12 | Liquid infant formula composition containing goat milk |
| TW105126465A TWI703931B (en) | 2015-08-18 | 2016-08-18 | Composition of infant liquid formula including goat milk and method for manufacturing the same |
| HK18112026.3A HK1252716A1 (en) | 2015-08-18 | 2018-09-19 | Liquid infant formula composition containing goat milk |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150116254A KR101640890B1 (en) | 2015-08-18 | 2015-08-18 | Composition of infant liquid formula including goat milk |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160086860A Division KR102050578B1 (en) | 2015-08-18 | 2016-07-08 | Composition of infant liquid formula including goat milk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101640890B1 true KR101640890B1 (en) | 2016-07-19 |
Family
ID=56616485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150116254A KR101640890B1 (en) | 2015-08-18 | 2015-08-18 | Composition of infant liquid formula including goat milk |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101640890B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017030330A1 (en) * | 2015-08-18 | 2017-02-23 | 주식회사 엘지생활건강 | Liquid infant formula composition containing goat milk |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1084868A (en) * | 1996-09-12 | 1998-04-07 | Nisshin Flour Milling Co Ltd | Milk replacer composition and its production |
| JP3152977B2 (en) * | 1991-12-02 | 2001-04-03 | 明治乳業株式会社 | Milk protein material containing casein protein similar to human milk and method for producing the same |
| US20110281012A1 (en) * | 2007-04-16 | 2011-11-17 | Friesland Brands B.V. | Functional serum protein product for use in infant food and therapeutic compositions and methods for the preparation thereof |
| US20120040051A1 (en) * | 2010-08-13 | 2012-02-16 | Kwan-Han Chen | Process for preparing milk product enhanced with galactooligosaccharide and easily absorbable, and functional milk product prepared therewith |
-
2015
- 2015-08-18 KR KR1020150116254A patent/KR101640890B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3152977B2 (en) * | 1991-12-02 | 2001-04-03 | 明治乳業株式会社 | Milk protein material containing casein protein similar to human milk and method for producing the same |
| JPH1084868A (en) * | 1996-09-12 | 1998-04-07 | Nisshin Flour Milling Co Ltd | Milk replacer composition and its production |
| US20110281012A1 (en) * | 2007-04-16 | 2011-11-17 | Friesland Brands B.V. | Functional serum protein product for use in infant food and therapeutic compositions and methods for the preparation thereof |
| US20120040051A1 (en) * | 2010-08-13 | 2012-02-16 | Kwan-Han Chen | Process for preparing milk product enhanced with galactooligosaccharide and easily absorbable, and functional milk product prepared therewith |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017030330A1 (en) * | 2015-08-18 | 2017-02-23 | 주식회사 엘지생활건강 | Liquid infant formula composition containing goat milk |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100955408B1 (en) | Infant formula compositions comprising increased amounts of alpha-lactalbumin | |
| US20130064923A1 (en) | Liquid Milk Beverage For Toddlers | |
| CN106937677B (en) | Total-nutrient formula dairy product added with coconut particles and preparation method thereof | |
| US20100178361A1 (en) | Method of stabilizing iron compositions with milk protein | |
| RU2703177C2 (en) | Infant nutrition with hydrolysed protein, ionic calcium and palmitic acid | |
| CN110621164B (en) | High protein acidified liquid dairy products having reduced viscosity, methods of production thereof and related ingredients | |
| KR101639676B1 (en) | Infant liquid formula composition and its manufacturing process | |
| KR101640890B1 (en) | Composition of infant liquid formula including goat milk | |
| CN112056404A (en) | Formula milk powder for pregnant women and preparation method thereof | |
| KR102050578B1 (en) | Composition of infant liquid formula including goat milk | |
| TWI703931B (en) | Composition of infant liquid formula including goat milk and method for manufacturing the same | |
| RU2703172C2 (en) | Feeding for infants with hydrolysed protein and palmitic acid | |
| KR101981606B1 (en) | Infant liquid formula composition and its manufacturing process | |
| KR101863165B1 (en) | Manufacturing Method of Infant Formula Milk for Preventing Aggregation of Nutritional Component | |
| KR102536585B1 (en) | Liquid milk composition | |
| RU2384069C1 (en) | Formula for production of sterilised milk product of baby food based on goat's milk from birth to five months of age | |
| JP6753255B2 (en) | Liquid nutritional composition | |
| CN115500398B (en) | Formula milk product rich in beta-casein and preparation method thereof | |
| EP4030921B1 (en) | Whey-based nutritional compositions fortified with calcium | |
| JP2019519229A (en) | Enhanced stability and mouthfeel of fortified and aseptically processed beverages | |
| CN101317608B (en) | Liquid milk with additive serum albumin for baby of 12 to 36 months age | |
| KR20190084937A (en) | Infant liquid formula composition and its manufacturing process | |
| WO2020196426A1 (en) | Method for producing neutral liquid protein beverage containing whey protein | |
| KR20170085475A (en) | Infant liquid formula composition and its manufacturing process | |
| KR101752197B1 (en) | Manufacturing method of infant formula containing vegetable docosahexaenoic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20190702 Year of fee payment: 4 |